The company announced today that AliveCor has updated the capabilities of its mobile ECG device to recognize three other types of heart disease.
Sinus rhythm with supraventricular ectopic disease (SVE), sinus rhythm with ventricular premature beats (PVC) and sinus rhythm with wide QRS are now on the desktop of AliveCor’s KardiaMobile ECG device series. These devices have detected atrial fibrillation, bradycardia (slow heart rate) and tachycardia (high heart rate).
The new decision is the result of an update to AliveCor's KardiaAI software, which was approved by the FDA in November. According to the document, the updated software is particularly compatible with KardiaMobile System, Triangle System and Omron Model BP7900 blood pressure monitor + ECG (two heart health device companies cooperated in 2018).
The "Advanced Measurement" feature is available today to subscribers of AliveCor's KardiaCare product.
By better characterizing the individual's heart rhythm, providers can better understand the symptoms that patients exhibit and how they adapt to their overall heart health. These patients will be able to record and upload their readings immediately from the comfort of their homes-a key advantage, whether in the ongoing COVID-19 pandemic or the difficulty of finding intermittent abnormalities outside the hospital.
AliveCor's announcement also quickly pointed out that these new features are the main difference between its connected ECG products and competitors. In addition to selling six-lead ECG to consumers instead of single-lead devices, AliveCor noted that its software-enabled devices provide more detailed information than other personal ECG systems that can only detect general atrial fibrillation.
AliveCor's software and equipment are alternatives to continuous heart monitoring platforms, such as sticky ECG patches, which can collect less detailed readings over a longer period of time.
Instead, its direct competition in the mobile ECG market today mainly comes from consumer products such as Apple Watch, Samsung Galaxy Watch and Fitbits, which use built-in sensors and proprietary software to detect atrial fibrillation and encourage wearers to consult medical professionals.
Therefore, AliveCor decided to stop selling KardiaBand in the second half of 2019, which is an ECG wristband designed for the early version of Apple Watch, which is not surprising. In addition, the mobile electrocardiogram manufacturer has infringed on three arrhythmia patents owned by AliveCor a few months ago that the technology giant's electrocardiogram tool.
In the past year or so, AliveCor has been relatively active. In addition to the aforementioned FDA approval, it also launched the KardiaCare digital subscription service and raised $65 million from investors.
Its technology is also the subject of a paper published today in Circulation, in which researchers at AliveCor and Mayo Clinic have developed an artificial intelligence algorithm that can be used with the company’s six-lead device to estimate A 12-lead ECG reading is usually required.
The latest news of digital health will be sent to your inbox every day.
© 2021 MobiHealthNews is a publication of HIMSS Media
The latest news of digital health will be sent to your inbox every day.